Olaparib + Physician's choice + Trabectedin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cancers With DNA Repair-Deficiency
Conditions
Cancers With DNA Repair-Deficiency
Trial Timeline
Oct 25, 2018 → Dec 19, 2023
NCT ID
NCT03127215About Olaparib + Physician's choice + Trabectedin
Olaparib + Physician's choice + Trabectedin is a phase 2 stage product being developed by AstraZeneca for Cancers With DNA Repair-Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03127215. Target conditions include Cancers With DNA Repair-Deficiency.
What happened to similar drugs?
0 of 3 similar drugs in Cancers With DNA Repair-Deficiency were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03127215 | Phase 2 | Completed |
Competing Products
20 competing products in Cancers With DNA Repair-Deficiency